Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jul 02, 2024 3:40pm
139 Views
Post# 36115026

RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work
I do have a question which no one seems to be able to answer in regards to the patents.

This is from the Jan. 2023 investor presentation.

31
Robust Intellectual Property Portfolio
As of January 18, 2023
240 patents issued worldwide, including 21 US and 11 Canadian
17 pending applications worldwide
Reovirus issued patent claims cover:
Compositions of matter comprising reovirus
Through 2028 and extendable to 2033

It always previously stated the above for many previous presentations and always said that they were extendable but never said under what circumstances.

And now it states

147 patents issued worldwide, including 13 US and 7 Canadian
16 pending applications worldwide

Robust Intellectual Property Portfolio
Reovirus issued patent claims cover:
Compositions of matter comprising reovirus
Patent rights extend to at least the end of 2031


As you can see in the past 1.5 years we have lost almost 100 patents (maybe redundant maybe not) but also 2 years on the extendable part. So what has changed?

So my big question is why do they not just extend the patents that they keep talking about so as to not have to worry about impinging on the possible timeframes if there is no approval yet in place by the time the original patents expire.

<< Previous
Bullboard Posts
Next >>